期刊
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
卷 37, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.nano.2021.102434
关键词
Atherosclerosis; Liposomes; 3D culture; Spheroids; Simvastatin; Inflammation
资金
- NTU-Northwestern Institute for Nanomedicine [04INS000156C150]
Atherosclerosis is a multifactorial disease triggered by risk factors such as high cholesterol, high blood pressure, and unhealthy lifestyle. In this study, a simvastatin-loaded nanoliposomal formulation (LIPOSTAT) was developed to deliver the drug into atherosclerotic plaque, reducing inflammation and promoting cholesterol efflux.
Atherosclerosis is a multifactorial disease triggered and sustained by risk factors such as high cholesterol, high blood pressure and unhealthy lifestyle. Inflammation plays a pivotal role in atherosclerosis pathogenesis. In this study, we developed a simvastatin (STAT) loaded nanoliposomal formulation (LIPOSTAT) which can deliver the drug into atherosclerotic plaque, when administered intravenously. This formulation is easily prepared, stable, and biocompatible with minimal burst release for effective drug delivery. 2D and 3D in vitro models were examined towards anti-inflammatory effects of STAT, both free and in combination with liposomes. LIPOSTAT induced greater cholesterol efflux in the 2D foam cells and significantly reduced inflammation in both 2D and 3D models. LIPOSTAT alleviated inflammation by reducing the secretion of early and late phase pro-inflammatory cytokines, monocyte adherence marker, and lipid accumulation cytokines. Additionally, the 3D foam cell spheroid model is a convenient and practical approach in testing various anti-atherosclerotic drugs without the need for human tissue. (C) 2021 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据